Table 2.
Effect of ANGPTL3 inhibition on plasma lipids, Angptl3 mRNA, and protein in LDLr−/− mice
| Treatment Group | TPC (mg/dl) | TG (mg/dl) | HDL-C (mg/dl) | Angptl3 mRNA (%PBS) | ANGPTL3 Protein (ng/ml) |
|---|---|---|---|---|---|
| PBS | 1,405 ± 145 | 442 ± 40 | 76 ± 3 | 100 ± 14 | 307 ± 23 |
| Control ASO (50 mg/kg) | 1,322 ± 96 | 454 ± 42 | 72 ± 4 | 102 ± 14 | 385 ± 31 |
| Angptl3 ASO (50 mg/kg) | 451 ± 26a,b | 66 ± 6a,b | 72 ± 4 | 12 ± 3a,b | 121 ± 9a,b |
| Angptl3ASO (15 mg/kg) | 895 ± 91a,b | 178 ± 28a,b | 84 ± 4 | 39 ± 6a,b | 199 ± 22a,b |
| Angptl3ASO (5 mg/kg) | 995 ± 69 | 275 ± 54 | 73 ± 6 | 62 ± 12 | 271 ± 13b |
| Angptl3ASO (1.5 mg/kg) | 1,508 ± 108 | 572 ± 84 | 74 ± 2 | 97 ± 16 | 338 ± 26 |
Values represent the mean ± SEM, n = 4–6/group of treatment.
a
Denotes a significant difference (P < 0.05) compared with PBS.
b
Denotes a significant difference (P < 0.05) compared with control ASO.